Cell therapy (Stem-cell derived) · Kills target cells · developed by Capricor
Deramiocel (CAP-1002) is an allogeneic cell therapy composed of cardiosphere-derived cells (CDCs) delivered intracoronary. The cells secrete bioactive elements including growth factors and exosomes, with immunomodulatory, anti-fibrotic, anti-inflammatory, and pro-angiogenic mechanisms. It is studied in myocardial infarction, heart failure, cardiomyopathy, and Duchenne muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05126758 | Phase 3 | Muscular Dystrophies | Active not recruiting | CAPR |
| NCT03406780 | Phase 2 | Muscular Dystrophies | Completed | CAPR |
| NCT02485938 | Phase 2 | Duchenne Muscular Dystrophy | Completed | CAPR |
| NCT01458405 | Phase 1/2 | Myocardial Infarction | Terminated | CAPR |
| NCT02293603 | Phase 1 | Dilated Cardiomyopathy (DCM) | Unknown | CAPR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CardiomyopathyDilated Cardiomyopathy (DCM)Duchenne Muscular DystrophyGenetic Diseases, InbornGenetic Diseases, X-LinkedHeart FailureIschemic CardiomyopathyMuscular DiseasesMuscular Disorders, AtrophicMuscular DystrophiesMuscular Dystrophy, DuchenneMyocardial InfarctionNervous System DiseasesNeuromuscular Diseases
Updated Oct 3, 2026. Something wrong or missing? Report it on the CAPR page.
See CAPR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CAPR catalysts and pipeline →